This is opening up again. I do believe when I attempted to get in a couple years ago your ALP had to be 1x5 above the normal:
At the time I qualified, happy to say I don’t right now - however I take an antibiotic daily for my autoimmune Rosacea so I was disqualified.
I think it is very exciting they are still taking participants. The one time I went on High Dose of Vanco was after a bad cat bite. Just happened ot have my labs done right before and a few weeks after. My ALP definitely dropped - so I’m encouraged to know that perhaps one day when push comes to shove Vanco might be a good fit for me - even though I am 56. Most say it works best in younger folks.
Here’s the info copied from an email:
Dear JENNIFER ST LORANT,
A feature of the PSC Partners Patient Registry is to provide researchers a way to communicate clinical trial opportunities to Registry participants.
Mayo Clinic has sought the Registry’s help in locating PSC patients interested in their vancomycin trial, Treating Adult Patients with Primary Sclerosing Cholangitis with Oral Vancomycin in a Randomized Trial .
Please find below Mayo Clinic’s message about the trial, followed by a Q&A conversation between the Registry Director Rachel Gomel and a Mayo study researcher.
Message from Mayo Clinic
Primary Sclerosing Cholangitis (PSC) Research Study
Mayo Clinic researchers are looking for people with Primary Sclerosing Cholangitis (PSC) to participate in a research study. The overall goal of this study is to examine the safety and effectiveness of daily dosing with oral vancomycin versus placebo.
What is PSC? PSC is a disease of the liver characterized by ongoing inflammation of the bile ducts, which can ultimately lead to cirrhosis and end-stage liver disease (ESLD).
What happens during the study? For each study participant, the study participation period will consist of 5 visits which include: the screening period of up to 1 month, treatment period for 18 months, and a follow-up period of up to 6 months. Participants will be randomized to either the placebo group or the active treatment group.
Who can participate? To participate in this study, you must:
- Be between 18 and 75 years old
- Have a diagnosis of PSC consistent with the guidelines published by the American Association for the Study of Liver Diseases (AASLD)
- Have had an ultrasound that excludes biliary obstruction and malignancy within 6 months of study entry
For more information :
Arizona: Saran Vaughn at 480-342-6487 or Vaughn.Saran@mayo.edu
Rochester: Mitchell Clayton at 507-284-2698 or Clayton.Mitchell@mayo.edu
Florida: Robert Brannock at 904-953-3238 or Brannock.Robert@mayo.edu
Dated: August 16, 2021